Fibrogen director James Schoeneck buys $105,040 in stock

Published 24/03/2025, 14:02
Fibrogen director James Schoeneck buys $105,040 in stock

James A. Schoeneck, a director at FibroGen Inc . (NASDAQ:FGEN), recently expanded his holdings in the company through two separate stock purchases, as the stock trades near $0.32, down nearly 88% over the past year. According to a regulatory filing, Schoeneck acquired a total of 300,000 shares over two days, March 20 and March 21, for a combined total of $105,040.

On March 20, Schoeneck purchased 250,000 shares at a weighted-average price of $0.352 per share, with the purchase price ranging from $0.3499 to $0.3593. The following day, he acquired an additional 50,000 shares at a weighted-average price of $0.3408, with prices ranging from $0.3341 to $0.3466.

These transactions were conducted indirectly through a trust, and after these purchases, Schoeneck’s total holdings in FibroGen increased to 373,722 shares.

In other recent news, FibroGen Inc. reported an unexpected earnings per share (EPS) of $0.18 for the fourth quarter of 2024, surpassing analyst forecasts of -$0.17. Despite the positive EPS surprise, the company continues to face revenue challenges, with Q4 2024 revenue declining to $3.1 million from $3.6 million the previous year. Additionally, for the full year 2024, FibroGen’s revenue fell to $29.6 million, down from $46.8 million in 2023. The company announced a significant transaction involving the sale of FibroGen China to AstraZeneca (NASDAQ:AZN) for approximately $160 million, which is expected to close by mid-2025. This move aims to streamline operations and pay down debt, extending the company’s cash runway into 2027. Analysts from William Blair and H.C. Wainwright engaged with FibroGen’s executives, exploring the company’s focus on its oncology pipeline and the potential development of roxadustat for anemia treatment. Despite the ongoing revenue decline, FibroGen plans to concentrate on advancing its oncology programs, including FG3246 and FG3180, and meeting with the FDA to discuss further development of roxadustat.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.